Aldosterone
Aldosterone is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target mineralocorticoid receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
— C03: Diuretics
— C03D: Aldosterone antagonists and other potassium-sparing agents
— C03DA: Aldosterone antagonists
H: Systemic hormonal preparations, excl. sex hormones and insulins
— H02: Corticosteroids for systemic use
— H02A: Corticosteroids for systemic use, plain
— H02AA: Mineralocorticoids for systemic use, plain
— H02AA01: Aldosterone
HCPCS
No data
Clinical
Clinical Trials
357 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypertension | D006973 | EFO_0000537 | I10 | 5 | 8 | 6 | 20 | 47 | 85 |
| Hyperaldosteronism | D006929 | — | E26 | 1 | 2 | 2 | 4 | 66 | 74 |
| Heart failure | D006333 | EFO_0003144 | I50 | 2 | 9 | 13 | 9 | 31 | 63 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | 3 | 7 | 8 | 9 | 26 |
| Chronic renal insufficiency | D051436 | — | N18 | — | 3 | 3 | 4 | 7 | 16 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | 1 | 2 | 2 | 4 | 6 | 14 |
| Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | 1 | 1 | 3 | 1 | 9 | 14 |
| Covid-19 | D000086382 | — | U07.1 | — | 2 | 3 | 1 | 9 | 13 |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | 3 | 3 | 2 | 6 | 13 |
| Healthy volunteers/patients | — | — | — | 6 | — | — | 2 | 4 | 12 |
Show 74 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myocardial infarction | D009203 | EFO_0000612 | I21 | — | 1 | 3 | — | 7 | 11 |
| Infarction | D007238 | EFO_0009463 | — | — | 1 | 3 | — | 6 | 10 |
| Adrenocortical adenoma | D018246 | — | — | — | — | 1 | — | 9 | 10 |
| Congenital adrenal hyperplasia | D000312 | — | E25.0 | — | — | 1 | — | 6 | 7 |
| Atherosclerosis | D050197 | EFO_0003914 | I25.1 | — | — | 1 | — | 2 | 3 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 2 | 1 | — | — | 3 |
| Renin-angiotensin system | D012084 | — | — | 1 | 2 | 1 | — | 1 | 3 |
| Ventricular remodeling | D020257 | — | — | — | — | 1 | — | 2 | 3 |
| Polycystic kidney diseases | D007690 | — | Q61.3 | — | — | 2 | — | — | 2 |
| Coronary disease | D003327 | — | — | — | — | 1 | — | 1 | 2 |
Show 10 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv infections | D015658 | EFO_0000764 | B20 | — | 2 | — | — | 1 | 3 |
| Vitamin d deficiency | D014808 | EFO_0003762 | E55 | — | 1 | — | — | 1 | 2 |
| Psychological stress | D013315 | — | — | — | 1 | — | — | 1 | 2 |
| Fatty liver | D005234 | EFO_0003934 | — | — | 1 | — | — | 1 | 2 |
| Wounds and injuries | D014947 | — | T14.8 | — | 1 | — | — | 1 | 2 |
| Arrhythmogenic right ventricular dysplasia | D019571 | Orphanet_247 | I42.8 | — | 1 | — | — | — | 1 |
| Right ventricular dysfunction | D018497 | — | — | — | 1 | — | — | — | 1 |
| Congenital heart defects | D006330 | — | Q24.9 | — | 1 | — | — | — | 1 |
| Tetralogy of fallot | D013771 | EFO_0004894 | Q21.3 | — | 1 | — | — | — | 1 |
| Ascites | D001201 | — | R18 | — | 1 | — | — | — | 1 |
Show 11 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Postural orthostatic tachycardia syndrome | D054972 | — | G90.A | 1 | — | — | — | 2 | 3 |
| Glucose metabolism disorders | D044882 | — | — | 1 | — | — | — | 1 | 2 |
| Pulmonary hypertension | D006976 | EFO_0001361 | I27.20 | 1 | — | — | — | 1 | 2 |
| Orthostatic intolerance | D054971 | — | — | 1 | — | — | — | — | 1 |
| Metabolic diseases | D008659 | EFO_0000589 | E88.9 | 1 | — | — | — | — | 1 |
| Endocrine system diseases | D004700 | EFO_0001379 | E34.9 | 1 | — | — | — | — | 1 |
| Therapeutic equivalency | D013810 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Adenoma | D000236 | — | — | — | — | — | — | 13 | 13 |
| Cushing syndrome | D003480 | EFO_0003099 | E24 | — | — | — | — | 6 | 6 |
| Left ventricular dysfunction | D018487 | — | — | — | — | — | — | 4 | 4 |
| Pituitary acth hypersecretion | D047748 | EFO_1001110 | E24.0 | — | — | — | — | 4 | 4 |
| Hyperplasia | D006965 | EFO_0000536 | — | — | — | — | — | 4 | 4 |
| Adrenogenital syndrome | D047808 | — | E25.9 | — | — | — | — | 4 | 4 |
| Acute kidney injury | D058186 | — | N17 | — | — | — | — | 3 | 3 |
| Ventricular dysfunction | D018754 | — | — | — | — | — | — | 3 | 3 |
| Adrenal insufficiency | D000309 | — | — | — | — | — | — | 3 | 3 |
| Adrenalectomy | D000315 | — | — | — | — | — | — | 3 | 3 |
Show 77 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Aldosterone |
| INN | aldosterone |
| Description | Aldosterone is a pregnane-based steroidal hormone produced by the outer-section (zona glomerulosa) of the adrenal cortex in the adrenal gland, and acts on the distal tubules and collecting ducts of the kidney to cause the conservation of sodium, secretion of potassium, increased water retention, and increased blood pressure. The overall effect of aldosterone is to increase reabsorption of ions and water in the kidney. It has a role as a human metabolite and a mouse metabolite. It is an 11beta-hydroxy steroid, a 21-hydroxy steroid, a 18-oxo steroid, a 20-oxo steroid, a C21-steroid hormone, a steroid aldehyde, a 3-oxo-Delta(4) steroid, a primary alpha-hydroxy ketone and a mineralocorticoid. It derives from a hydride of a pregnane. |
| Classification | Small molecule |
| Drug class | steroids (androgens, anabolics); antiandrogens |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C=O)[C@@H](C(=O)CO)CC[C@@H]12 |
Identifiers
| PDB | — |
| CAS-ID | 52-39-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL273453 |
| ChEBI ID | 27584 |
| PubChem CID | 5839 |
| DrugBank | DB04630 |
| UNII ID | 4964P6T9RB (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
NR3C2
NR3C2
Organism
Homo sapiens
Gene name
NR3C2
Gene synonyms
MCR, MLR
NCBI Gene ID
Protein name
mineralocorticoid receptor
Protein synonyms
aldosterone receptor, mineralocorticoid receptor 1, mineralocorticoid receptor 2, mineralocorticoid receptor delta, Nuclear receptor subfamily 3 group C member 2
Uniprot ID
Mouse ortholog
Nr3c2 (110784)
mineralocorticoid receptor (Q8VII8)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 91,767 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
20 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use